Related Experiment Video
Updated: May 16, 2026

QTL Mapping and CRISPR/Cas9 Editing to Identify a Drug Resistance Gene in Toxoplasma gondii
Published on: June 22, 2017
Can inhA mutation predict ethionamide resistance?
1P D Hinduja National Hospital and Medical Research Centre, Mumbai, India.
Setting:
A tertiary care centre in Mumbai, India.
Objective:
To estimate the extent of association between inhA mutant isoniazid (INH) resistant strains and ethionamide (ETH) resistance.
Design:
A total of 140 clinical isolates processed for INH and ETH phenotypic drug susceptibility testing, and molecularly processed with the line-probe assay (LPA) Genotype® MTBDRplus, were considered.
Results:
Among the 112 phenotypically determined INH-resistant strains, 69 (61.6%) strains were ETH-resistant. An inhA promoter mutation was identified in 24 (21.4%) INH-resistant isolates, 21 (87.5%) of which were ETH-resistant (P < 0.0001).
Conclusion:
An inhA promoter mutation could be considered as a marker for the determination of ETH resistance in India, where the use of LPA is being expanded.
Related Concept Videos
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Drug toxicity: Idiosyncratic Reactions
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
